Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
Department of Surgery, Washington University School of Medicine, St Louis, MO.
S
S
So
C
C
Mayo
C
C
McCullough
M
M
Jendrisak
S
S
Woodle
W
W
Marsh
T
T
Bailey
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D002648:Child; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D015774:Ganciclovir / Q000627:therapeutic use*; D006084:Graft Rejection / Q000473:pathology / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D015774:Ganciclovir